The safety or risk of antihistamine use in pregnancy: Reassuring data are helpful but not sufficient

Journal of Allergy and Clinical Immunology: In Practice

Volumn 1, Issue 6, 2013, Pages 675-676

  Honein, Margaret A ^a   Moore, Cynthia A ^a  

^a NATIONAL CENTER ON BIRTH DEFECTS AND DEVELOPMENTAL DISABILITIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIHISTAMINIC AGENT; CORTICOSTEROID; LORATADINE; NON PRESCRIPTION DRUG;

ADVERSE OUTCOME; AUTISM; BIRTH DEFECT; CLEFT PALATE; DEVELOPMENTAL DISORDER; DRUG INDICATION; DRUG SAFETY; DRUG USE; EDITORIAL; EPILEPSY; EVIDENCE BASED MEDICINE; FETUS DEVELOPMENT; FETUS GROWTH; GROWTH DISORDER; HIGH RISK PREGNANCY; HUMAN; MEDICAL INFORMATION; MENTAL DEVELOPMENT; NAUSEA AND VOMITING; NERVOUS SYSTEM DEVELOPMENT; PREGNANCY OUTCOME; PREMATURE LABOR; PRENATAL DRUG EXPOSURE; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; RISK MANAGEMENT; SPINAL DYSRAPHISM; SPONTANEOUS ABORTION; SYMPTOM; ABNORMALITIES, DRUG-INDUCED; FEMALE; PREGNANCY; PREGNANCY COMPLICATIONS;

ABNORMALITIES, DRUG-INDUCED; FEMALE; HISTAMINE ANTAGONISTS; HUMANS; PREGNANCY; PREGNANCY COMPLICATIONS;

EID: 84887009224     PISSN: 22132198     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaip.2013.08.005     Document Type: Editorial

References (12)

1. Quinla J.D., Hill D.A. Nausea and vomiting of pregnancy. Am Fam Physician 2003, 68:121-128.
2. Lacroix R., Eason E., Melzack R. Nausea and vomiting during pregnancy: a prospective study of its frequency, intensity, and patterns of change. Am J Obstet Gynecol 2000, 182:931-937.
3. Thorpe P.G., Gilboa S.M., Hernandez-Diaz S., Lind J., Cragan J.D., Briggs G., et al. Medications in the first trimester of pregnancy: most common exposures and critical gaps in understanding fetal risk. Pharmacoepidemiol Drug Saf 2013, 22:1013-1018.
4. Li Q., Mitchell A.A., Werler M.M., Yau W.P., Hernandez-Diaz S. Antihistamine use in early pregnancy and risk of birth defects. JAllergy Clin Immunol Pract 2013, 1:666-674.
5. Sullivan P.W., Nair K.V., Patel B.V. The effect of the Rx-to-OTC switch of loratadine and changes in prescription drug benefits on utilization and cost of therapy. Am J Manag Care 2005, 11:374-382.
6. Peters S.L., Lind J.N., Humphrey J.R., Friedman J.M., Honein M.A., Tassinari M.S., et al. Safe lists for medications in pregnancy: inadequate evidence base and inconsistent guidance from Web-based information, 2011. Pharmacoepidemiol Drug Saf 2013, 22:324-328.
7. Gilboa S.M., Strickland M.J., Olshan A.F., Werler M.M., Correa A. National Birth Defects Prevention S. Use of antihistamine medications during early pregnancy and isolated major malformations. Birth Defects Res A Clin Mol Teratol 2009, 85:137-150.
8. Kallen B. Use of antihistamine drugs in early pregnancy and delivery outcome. JMatern Fetal Neonatal Med 2002, 11:146-152.
9. Bakhireva L.N., Jones K.L., Schatz M., Johnson D., Chambers C.D. Organization of Teratology Information Services Research Group. Asthma medication use in pregnancy and fetal growth. JAllergy Clin Immunol 2005, 116:503-509.
10. Christensen J., Gronborg T.K., Sorensen M.J., Schendel D., Parner E.T., Pedersen L.H., et al. Prenatal valproate exposure and risk of autism spectrum disorders and childhood autism. JAMA 2013, 309:1696-1703.
11. Cummings C., Stewart M., Stevenson M., Morrow J., Nelson J. Neurodevelopment of children exposed in utero to lamotrigine, sodium valproate and carbamazepine. Arch Dis Child 2011, 96:643-647.
12. Battino D., Tomson T. Management of epilepsy during pregnancy. Drugs 2007, 67:2727-2746.